Product Name
|
Pharmaceutical Intermediate Glipizide Powder CAS 29094-61-9 Glipizide Used in Hypoglycemia |
Appearance
|
white powder |
Assay
|
99%min, 98.0% --101.0% |
Test
|
HPLC
|
Certificate
|
ISO 9001
|
CAS
|
29094-61-9 |
MF | C21H27N5O4S |
Storage Temperature |
Cool Dry Place
|
glipizide1, chemically named N-[2-[4-[[[[(cyclohexyl amino) carbonyl] amino] sulfonyl] phenyl] ethyl] -
5-methylpyrazine-2-formamide, the second generation of oral sulfonylureas, launched in the United States in
1984, It can promote the secretion by pancreatic β cells and enhance the effect on target
tissues. It can also inhibit the secretion of glucagon by pancreatic islet α cells, inhibit the decomposition of liver
glycogen, and promote muscle utilization and consumption of glucose. It is clinically used for patients with mild
and moderate type 2 diabetes who failed to achieve good results with diet control alone.
1. Hypoglycemic effect: This product is the second generation oral sulfonylurea hypoglycemic drug, which
has definite effect on type II type diabetes mellitus. It acts on islet beta cells to promote endogenous
secretion. Inhibit hepatic glycogen decomposition and promote peripheral tissue glucose utilization;
The sensitivity of target tissues can also be changed through the extra-pancreatic action,
which may be related to the increase of plasma membrane receptors and post-receptor effects.
2. Reduce the serum triglyceride level and accelerate the transformation of cholesterol in the blood.
3. Reduce the cohesion of platelet and improve the decomposition and absorption ability of fibrin.
Company Information
Our Certificate
Our Service
Our Research
Packaging & Logistics